MedTrace Logo

A Phase II Open-label Single-arm Study to Evaluate the Efficacy and Safety of ADSCs in Subjects With Liver Cirrhosis

NCT04088058 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-04-10

No results posted yet for this study

Summary

The aim of the investigators study was to investigate the safety and efficacy of autologous ADSCs for the clinical treatment of liver cirrhosis.

Conditions

Interventions

DRUG

GXHPC1

autologous ADSCs

Sponsors & Collaborators

  • Gwo Xi Stem Cell Applied Technology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Huang ka Wen, Director · National Taiwan University Hospital

  • Lee Mi Che, Director · Hualien Tzu Chi General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-16
Primary Completion
2025-04-19
Completion
2025-04-19

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04088058 on ClinicalTrials.gov